Prelude Therapeutics (PRLD) Cash & Equivalents (2019 - 2026)

Prelude Therapeutics has reported Cash & Equivalents for 8 years, with the latest figure at $84.8 million in Q1 2026.

• Quarterly Cash & Equivalents rose 91.37% year-over-year to $84.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84.8 million (up 91.37% YoY) and the FY2025 annual result came in at $35.3 million, up 113.44% from the prior year.
• Cash & Equivalents advanced to $84.8 million in Q1 2026 per PRLD's latest filing, from $35.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $84.8 million in Q1 2026 and troughed at $15.2 million in Q3 2024.
• A 5-year average of $40.3 million and a median of $34.6 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents slumped 84.66% in 2022, then surged 213.16% in 2025.
• Over 5 years, Cash & Equivalents stood at $34.6 million in 2022, then slipped by 15.34% to $29.3 million in 2023, then plunged by 43.69% to $16.5 million in 2024, then jumped by 113.44% to $35.3 million in 2025, then jumped by 140.53% to $84.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $84.8 million, $35.3 million, and $47.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.